Merus NV (FRA:2GH)
€ 48.4 -0.4 (-0.82%) Market Cap: 3.34 Bil Enterprise Value: 3.04 Bil PE Ratio: 0 PB Ratio: 8.88 GF Score: 61/100

Merus NV at Jefferies Healthcare Conference Transcript

Jun 07, 2023 / 03:30PM GMT
Release Date Price: €21
Maury Raycroft
Jefferies, LLC - Analyst

Hi, everyone. Thanks for joining us. My name is Maury Raycroft. And I'm one of the biotech analysts at Jefferies. I'd like to welcome Bill Lundberg, the CEO of Merus. And we're going to do a fireside chat discussion. So maybe to start off, Bill, if you want to give a brief intro to Merus.

Bill Lundberg
Merus N.V. - President, CEO, Principal Financial Officer & Executive Director

Merus is an oncology-focused bispecific and multi-specific antibody company based on foundational technology that allows us to look through hundreds of thousands of potential candidate molecules to find the best ones to bring in the clinic. And while we don't necessarily think that guarantees success in the clinic based on the recent clinical data, we've been able to show across our portfolio. We're really encouraged that it may give us an advantage as we bring clinical candidates forward.

We have four clinical-stage candidates, I'm sure we'll discuss today. Three of which are really showing legs. So we're really quite encouraged

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot